Evidence map›Paper›PMID 29181175›Full record

ArticleMolecular and clinical oncology2017

Peripheral blood neutrophil count as a prognostic factor for patients with hepatocellular carcinoma treated with sorafenib.

Jia Yuan, Hongming Liang, Jinghuan Li, Miao Li, Bei Tang, Hui Ma, Xiaoying Xie, Xin Yin, Lan Zhang, Zhenggang Ren

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular and clinical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Neutrophils as potential therapeutic targets in hepatocellular carcinoma.Nature reviews. Gastroenterology & hepatology · 2022
    Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jia YuanLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China.
Hongming LiangLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China.
Jinghuan LiLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China.
Miao LiLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China.
Bei TangLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China.
Hui MaLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China.
Xiaoying XieLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China.
Xin YinLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China.
Lan ZhangLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China.
Zhenggang RenLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sorafenib is currently the only efficient molecular targeted therapy for hepatocellular carcinoma (HCC), although its effect is relatively moderate and variable between individuals. The present study aimed to evaluate the significance of peripheral blood neutrophils in the prognosis of HCC patients treated with sorafenib. A total of 464 patients with HCC were treated with sorafenib at Zhongshan Hospital (Shanghai, China) between January 1st, 2008 and December 31st, 2012, among which 120 patients were enrolled in the study. The optimal cutoff point for low vs. high neutrophil count (3.65×10

Indexed as

hepatocellular carcinomanomogramperipheral neutrophilsprognosissorafenib

Identifiers

PMID29181175
PMCPMC5700259

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.